StockData

Generate Biomedicines, Inc. (GENB) stock

GENBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$9.84−0.65 (-6.20%)

Close on Nov 17, 2026Market cap $1.26BP/E –Yield –

Earnings

Generate Biomedicines's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue, Q3 FY2026
$4.20M
EPS, Q3 FY2026
-$0.68
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Generate Biomedicines's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q3 FY2026ended Sep 30, 2026Nov 12, 2026before the open$4.20M–-$0.68Release
Q2 FY2026ended Jun 30, 2026Aug 6, 2026before the open$6.30M–-$0.52Release
Q1 FY2026ended Mar 31, 2026May 7, 2026before the open$7.20M––Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Generate Biomedicines has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Generate Biomedicines puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Generate Biomedicines filed with the SEC as exhibits to Form 8-K or 6-K

See a number that looks wrong?